Posted in Uncategorized
Sybrava (siRNA): The Next Marathon in ASCVD Management
Sybrava For decades, cardiologists have focused on one goal: lowering LDL cholesterol (“bad cholesterol”) to prevent heart attacks and strokes. Yet despite high-intensity statins, ezetimibe, and lifestyle modification, many patients with Atherosclerotic Cardiovascular Disease (ASCVD) still fail to achieve guideline-recommended LDL-C targets. The question is no longer: “Should we lower LDL cholesterol?” The real question […]
